104 related articles for article (PubMed ID: 10630532)
1. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell line HT-29/B6.
Bode H; Schmidt W; Schulzke JD; Fromm M; Zippel T; Wahnschaffe U; Bendfeldt K; Riecken EO; Ullrich R
AIDS; 1999 Dec; 13(18):2595-7. PubMed ID: 10630532
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
3. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
5. Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT-29/B6.
Bode H; Schmidt W; Schulzke JD; Fromm M; Riecken EO; Ullrich R
Ann N Y Acad Sci; 2000; 915():117-22. PubMed ID: 11193566
[No Abstract] [Full Text] [Related]
6. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
Hugen PW; Verweij-van Wissen CP; Burger DM; Wuis EW; Koopmans PP; Hekster YA
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):139-49. PubMed ID: 10360433
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Kuschak D; Mauss S; Schmutz G; Gantke B
Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
[TBL] [Abstract][Full Text] [Related]
8. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil does not alter nelfinavir pharmacokinetics.
Bratt G; Ståhle L
Ther Drug Monit; 2003 Apr; 25(2):240-2. PubMed ID: 12657921
[TBL] [Abstract][Full Text] [Related]
10. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
[TBL] [Abstract][Full Text] [Related]
11. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.
Rouquayrol M; Gaucher B; Roche D; Greiner J; Vierling P
Pharm Res; 2002 Nov; 19(11):1704-12. PubMed ID: 12458677
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
Klaus BD; Grodesky MJ
Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221
[No Abstract] [Full Text] [Related]
13. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.
Rouquayrol M; Gaucher B; Greiner J; Aubertin AM; Vierling P; Guedj R
Carbohydr Res; 2001 Nov; 336(3):161-80. PubMed ID: 11705466
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
[TBL] [Abstract][Full Text] [Related]
16. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
17. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
[TBL] [Abstract][Full Text] [Related]
18. Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma.
Janoly A; Bleyzac N; Favetta P; Gagneu MC; Bourhis Y; Coudray S; Oger I; Aulagner G
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 780(1):155-60. PubMed ID: 12383491
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir.
Taylor S; Back DJ; Drake SM; Workman J; Reynolds H; Gibbons SE; White DJ; Pillay D
J Antimicrob Chemother; 2001 Sep; 48(3):351-4. PubMed ID: 11532998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
